Gene-Editing Stocks Are Priced on Future Patients, Big Pharma on Today's Cash Flow

The first approved CRISPR therapy can cure sickle cell disease with a single treatment. The company that co-invented it reported almost no revenue last year. That is not a contradiction. It is how markets price medicine that has not yet reached most of its patients.

Our research desk drew on two Motley Fool comparisons. One set CRISPR Therapeutics against Vertex Pharmaceuticals. The other set Bristol Myers Squibb against Pfizer. The desk's point: a company built on one new product trades on adoption and the next trial, while a diversified drugmaker trades on cash flow and dividends.

Both comparisons are real. Both were published in June 2026, not the week our desk wrote about them. Treat this as useful context rather than breaking news.

The Motley Fool's June 27 comparison reported that CRISPR Therapeutics had about $3.5 million in 2025 revenue and a net loss of about $582 million. Its price-to-sales ratio was roughly 1,270. Vertex had about $12 billion in revenue, about $4 billion in profit, and a price-to-sales ratio near 10.

The two companies share the same product. Casgevy, approved for sickle cell disease and transfusion-dependent beta thalassemia, is co-owned by the pair, with Vertex leading sales. Profits and losses are split 60% to Vertex and 40% to CRISPR. Vertex earns most of its money from its cystic fibrosis medicines, Trikafta and Alyftrek.

The same report flagged risks that come with the single-product model. CRISPR raised $600 million through convertible notes in early 2026 to fund its work, and it faces patent litigation from ToolGen. A company without earnings must keep raising money, and each raise dilutes existing owners. Vertex, by contrast, generated about $3.2 billion in free cash flow.

The Pfizer and Bristol Myers Squibb comparison, published June 4, looked mostly at dividends. Both traded just under nine times forward earnings. Pfizer yielded about 6.7% with a payout ratio over 60%. Bristol Myers yielded about 4.6% with a payout ratio near 40%. Analysts expected both companies' sales to slip in 2026.

The desk called Vertex and the big drugmakers diversified. Pfizer and Bristol Myers fit that description. Vertex does not, quite. It depends heavily on one disease franchise, cystic fibrosis. It is concentrated, just profitably so.

The desk also wrote that one safety signal or trial can move a gene-editing valuation. That is a fair general statement. It is not a forecast about any specific company.

Many longevity therapies will look like Casgevy, not like a daily pill. They will be one-time, complex, and expensive to deliver. Patients must travel to specialized centers, undergo cell collection and chemotherapy conditioning, and wait for recovery.

That slows uptake, and slow uptake is exactly what the market is pricing. A cure that reaches few patients earns little, however good the science. The bottleneck is often the delivery system, not the molecule.

For you

For readers, two lessons follow. First, a company's stock price tells you little about how well its therapy works. Second, the arrival of a real cure is a starting gun, not a finish line. Watch how many patients actually receive it.

There is a policy lesson too. If one-time cures are hard to finance, insurers and employers will need new payment models, such as paying over several years or paying only if the treatment keeps working.

• How quickly will treatment centers scale Casgevy infusions, and will insurers keep paying? • Can in-body gene editing, which needs no cell collection, make one-time cures easier to deliver? • Will patent disputes in gene editing change who earns from these products? Not financial advice. This article reports facts and context only.

• Quarterly Casgevy patient counts from Vertex: cell collections and infusions, not just revenue. • Data from in-body gene-editing programs, which could change delivery costs. • Pfizer's dividend coverage as its sales forecasts soften.

Claim What We Found Tier

OpenAI Shelved GPT-6.1 Astra After It Failed to Stay Within Scope Can Math Unmix Soil That Worms Have Blended? A Testable Idea, Rated 50 Percent Tencent Is Reported to Be Renting 100,000 AI Chips From Oracle, a Sign That Cloud Leases Can Route Around Chip Export Limits